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goal was highest when increasing the statin dose (0.406), fol-
lowed by changing to a different statin (0.387), adding an addi-
tional therapy to the statin (0.320), not changing therapy
(0.306), and changing the statin to an alternative therapy
(0.111). The decision with the lowest average cost-effective ratio
was increasing the statin dose ($331.75). Incremental analysis
showed the cost of getting one more patient to goal was the
lowest for changing to a different statin ($126.85), followed by
increasing the statin dose ($173.16), and changing to an alter-
native therapy ($868.38). Sensitivity analysis found robust
results for the probabilities of reaching goal. Cost data was sen-
sitive between the decisions of increasing statin dose and chang-
ing statins. CONCLUSION: The most cost-effective decisions in
this study were to increase the statin dose or change to a differ-
ent statin.
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OBJECTIVES: Statin therapy reduces the rate of cardiovascular
disease, but high costs in combination with a large population
eligible for treatment ask for priority setting. Although trials
agree on the size of the beneﬁt, economical analyses of statins
report contradictory results. METHODS: We reviewed cost
effectiveness analyses comparing statins with no treatment and
sought to synthesize cost effectiveness ratios for categories of risk
of coronary heart disease and age. Data Sources: Medline, the
British National Health Service Economic Evaluation database
and authors’ reference lists. We searched for studies comparing
statins to no treatment for the prevention of cardiovascular
disease in adult male populations. Reviews and meta-analyses
were excluded. Studies needed to present cost per Years of Life
Gained/Saved (YLS, YLG) as outcome. Studies comparing statins
with other statins, or other medicaments were excluded.
RESULTS: Twenty-four studies were included, yielding 216 cost
effectiveness ratios. As expected, cost effectiveness ratios increase
with decreasing absolute risk. However after stratiﬁcation by
absolute risk, heterogeneity of CER is large with outcomes
varying from savings to US$ 59,000 per life year saved in the
highest risk category and from US$6500 to 490,000 in the lowest
risk category Disagreement increased at lower levels of risk.
Absolute risk was the only signiﬁcant predictor of cost effec-
tiveness ratios. Various signiﬁcant interactions with absolute risk
were found. CONCLUSION: Statin therapy is cheap for high
levels of risk, but discrepancies exist at lower levels of risk.
Although the cost-effectiveness of statins depends mainly on
absolute risk, factors like age, funding source and methodologi-
cal variables might be behind the ample remaining heterogene-
ity of the CER after adjusting for absolute risk. Economic
analyses need to increase their transparency to reduce their 
vulnerability to bias and increase their reproducibility.
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OBJECTIVES: To compare the cost-effectiveness of amiodarone,
atrial septal pacing, amiodarone plus atrial septal pacing, in
addition to standard therapy with beta-blockers, to standard
therapy alone to prevent postoperative atrial ﬁbrillation in
patients undergoing open-heart surgery. METHODS: A piggy-
back cost-effectiveness analysis of a randomized, placebo-
controlled, 2 ¥ 2 factorial trial was conducted from a hospital
perspective. Charges were converted to costs using cost-to-
charge ratios. For the cost-effectiveness analysis, a joint distrib-
ution of costs and effectiveness was performed using the
nonparametric bootstrap method. RESULTS: The incidence of
postoperative atrial ﬁbrillation was 38%, 28%, 40%, and 16%
with standard care, amiodarone, atrial septal pacing, and amio-
darone plus atrial pacing, respectively (standard care vs. amio-
darone + pacing, p = 0.047; pacing vs. amiodarone + pacing, p
= 0.04). Total costs (mean ± SD) were $27,026 ± 30,226 in the
standard of care, $22,725 ± 17,661 in the amiodarone, $33,868
± 60,309 in the atrial septal pacing and $18,697 ± 8,174 in the
amiodarone plus atrial septal pacing groups (p = 0.27). In the
joint distribution cost-effectiveness analysis, compared to stan-
dard of care, the probability of lower cost but higher effect (supe-
riority) was 67% for amiodarone, 15% for atrial septal pacing,
and 97% for amiodarone plus atrial septal pacing. In multivari-
ate analysis, preoperative beta-blockers and amiodarone were
negatively associated with hospital costs (p < 0.05). CONCLU-
SIONS: Data suggest that amiodarone and amiodarone plus
atrial septal pacing are cost-effective compared to standard
therapy alone. Additional comparative studies between these
strategies are warranted to conﬁrm these ﬁndings.
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OBJECTIVES: To assess the use and cost of antilipemic drugs in
NHG institutions. METHODS: Dispensing data for antilipemic
drugs for various NHG institutions from Jan–Sept 2003 was
extracted and analysed using WHO ATC/DDD methodology
(version 2004). Setting: Primary care: NHG Polyclinics (NHGP).
Secondary care: Alexandra Hospital (AH) and Tan Tock Seng
Hospital (TTSH)—the latter has large general medicine and 
geriatric departments. Tertiary care: National University Hospi-
tal (NUH)—which has a large cardiac department and an active
lipid clinic. RESULTS: Statins accounted for 90% (88–92%)
whereas ﬁbrates accounted for 10% (8–12%) of total DDDs.
Lovastatin and simvastatin predominated the antilipemic drugs
use (83% of total DDDs). Although atorvastatin and pravas-
tatin’s usage was less than 7% of total DDDs, they accounted
for almost 50% of the total cost for antilipemic drugs. The total
usage and cost of antilipemic drugs were highest in NHGP. 
Atorvastatin and pravastatin were used more commonly in NUH
and TTSH (22% & 17% respectively) and resulted in higher
(2–3 times) average daily cost as compared to AH & NHGP (2%
for both institutions). The analysis also revealed that NUH &
NHGP have a higher average daily cost of bile acid sequestrants
and nicotinic acid derivatives respectively due to the use of more
expensive agents in these groups of drugs. CONCLUSIONS:
Generally, the utilisation proﬁle of the broad classes of
antilipemic drugs was similar across the four institutions. Statins
were the leading antilipemic drugs followed by ﬁbrates. Some
institutions used more expensive antilipemic drugs as compared
to the others. This has signiﬁcant cost implication to patients and
institutions. A closer analysis of patterns of antilipemic drug
